ASND Maintains Buy Rating by Citigroup -- Price Target Lowered to $330

gurufocus.com · 2026-10-26

Ascendis Pharma Analyst Rating Update On October 26, 2026, Citigroup analyst Eric Joseph maintained a Buy rating on Ascendis Pharma (ASND), while lowering th

Read the full story at gurufocus.com →